Results 181 to 190 of about 96,322 (259)
Allergy, EarlyView.ABSTRACT Allergen immunotherapy (AIT) has been acknowledged as the only disease‐modifying treatment for respiratory diseases since its introduction in 1911. Although the efficacy and safety have convincingly been established in numerous randomized clinical trials (RCTs), the AIT study results may vary substantially.
Roy Gerth van Wijk +10 more
wiley +1 more source
Asthma Remission From Childhood to Young Adulthood–A Population‐Based Cohort Study
Allergy, EarlyView.Among 257 participants with asthma at age 8 years, 39% achieved symptom‐based remission by age 24, 29% achieved clinical remission, and 18% achieved complete remission. Male sex increased the likelihood of symptom‐based remission, while food sensitization and overweight/obesity decreased the likelihood.
Lina Broström +6 more
wiley +1 more source
Allergy, EarlyView.Using MASK‐air app data from 1042 users across 2690 weeks, this study compared the impact of regular versus as‐needed allergic rhinitis medication on symptom control and treatment satisfaction. Mixed‐effects linear regression models and sensitivity analyses revealed no significant differences between the two approaches, with results for oral ...
Bernardo Sousa‐Pinto +38 more
wiley +1 more source
Allergy, EarlyView.ABSTRACT Among bacteria that are associated with the development and/or exacerbation of allergic/atopic diseases, several have been described to produce IgE‐binding components. However, only one bacterial protein, Bac s 1, is currently listed in the official database of the World Health Organization/International Union of Immunological Societies (WHO ...
Uta Jappe +24 more
wiley +1 more source
Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases
Allergy, EarlyView.ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz +22 more
wiley +1 more source
Allergy, EarlyView.The spectrum of allergic sensitization in mothers and their offspring was characterized at ages 1–5 years at an extract‐ and molecular level in a North American birth cohort. Fel d 1 was the primary sensitizer in mothers, followed by Phl p 1. Perennial allergen sensitization (Der f 1, Der p 1) was rare at age one but rose sharply by age five.
Mary Asumta Anyango Kodydek +14 more
wiley +1 more source
Dupilumab in Cholinergic Urticaria: An Exploratory Phase 2 Investigator‐Initiated Study
Allergy, EarlyView.
Annika Gutsche +15 more
wiley +1 more source
Allergy, EarlyView.In this Phase 2a trial, severely peanut‐allergic participants were randomized to abatacept versus placebo with peanut oral immunotherapy (OIT) for 24 weeks, followed by 12 weeks of OIT alone. No significant difference was observed for the primary efficacy outcome (the relative change from baseline in peanut‐specific/total IgE ratio at 24 weeks), but ...
Marie‐Lee Simard +12 more
wiley +1 more source
Rare Case of ALK-Positive Large B-Cell Lymphoma in a Young Adult: Diagnostic and Therapeutic Challenges. [PDF]
Case Rep HematolMenon T, Muir I, Emanuel A, Vile D.
europepmc +1 more source
A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial
British Journal of Haematology, EarlyView.The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...
Matthew J. Ahearne +28 more
wiley +1 more source